相似文献

1

Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.

Br J Cancer. 1976 Feb;33(2):137-43. doi: 10.1038/bjc.1976.18.

2

Proceedings: Cell mediated cytotoxicity (CMC) in patients with acute myeloblastic leukaemia receiving immunotherapy.

Br J Cancer. 1975 Aug;32(2):242. doi: 10.1038/bjc.1975.162.

3

Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.

Exp Hematol. 2008 Apr;36(4):486-94. doi: 10.1016/j.exphem.2007.11.012. Epub 2008 Jan 30.

4

Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.

Br J Cancer. 1979 Sep;40(3):391-6. doi: 10.1038/bjc.1979.193.

5

The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.

Cancer Sci. 2021 Aug;112(8):3233-3242. doi: 10.1111/cas.15014. Epub 2021 Jul 4.

6

Induction of cytotoxic lymphocyte subsets against leukemia by stimulation with AML blasts.

Med Oncol Tumor Pharmacother. 1993;10(1-2):13-9. doi: 10.1007/BF02987763.

7

The role of allogeneic cells in the stimulation of cell-mediated cytotoxicity to leukaemia cells. A family study.

Cancer Immunol Immunother. 1983;15(1):39-46. doi: 10.1007/BF00199460.

8

Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?

Expert Opin Biol Ther. 2001 Nov;1(6):1005-16. doi: 10.1517/14712598.1.6.1005.

9

Receptors for human immunoglobulin on acute myeloid leukaemic leucocytes.

Br J Cancer. 1976 Oct;34(4):346-58. doi: 10.1038/bjc.1976.177.

10

Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines.

Cytokines Cell Mol Ther. 2000 Sep;6(3):127-34. doi: 10.1080/mccm.6.3.127.134.

引用本文的文献

1

Susceptibility of human leukaemias to cell-mediated cytotoxicity by interferon-treated allogeneic lymphocytes.

Cancer Immunol Immunother. 1982;13(1):56-61. doi: 10.1007/BF00200202.

2

In vitro stimulation of cell-mediated cytotoxicity by acute leukaemias.

Br J Cancer. 1981 Feb;43(2):157-68. doi: 10.1038/bjc.1981.24.

3

Response of remission lymphocytes to autochthonous leukaemic myeloblasts.

Br J Cancer. 1976 May;33(5):501-11. doi: 10.1038/bjc.1976.81.

4

Suppression of lymphoproliferative responses to alloantigens by autologous AML cells.

Clin Exp Immunol. 1979 Jan;35(1):53-61.

5

Stimulation of human lymphocytes in vitro by leucocytes from patients with untreated acute myeloid leukaemia.

Clin Exp Immunol. 1977 Aug;29(2):229-39.

6

In vitro generation of tumor-specific cytotoxic lymphocytes. Secondary allogeneic mixed tumor lymphocyte culture of normal murine spleen cells.

J Exp Med. 1977 Aug 1;146(2):468-82. doi: 10.1084/jem.146.2.468.

本文引用的文献

1

Phenotypic expressions of the major histocompatibility locus in man (HL-A): leukocyte antigens and mixed leukocyte culture reactivity.

J Exp Med. 1968 Oct 1;128(4):623-37. doi: 10.1084/jem.128.4.623.

2

Recognition of leukaemia cells as foreign before and after autoimmunization.

Br Med J. 1971 Feb 27;1(5747):486-9. doi: 10.1136/bmj.1.5747.486.

3

Mixed lymphocyte cultures produce effector cells: model in vitro for allograft rejection.

Science. 1970 Apr 3;168(3927):133-5. doi: 10.1126/science.168.3927.133.

4

An experimental model of active immunotherapy preceded by cytoreductive chemotherapy.

Eur J Cancer (1965). 1970 Dec;6(6):557-9. doi: 10.1016/0014-2964(70)90078-2.

5

Cytotoxicity against human leukaemic cells. I. Demonstration of antibody-dependent lymphocyte killing of human allogeneic myeloblasts.

Clin Exp Immunol. 1973 Jun;14(2):159-67.

6

Auto-immunization with acute leukemia cells: demonstration of increased lymphocyte responsiveness.

Int J Cancer. 1973 May;11(3):521-6. doi: 10.1002/ijc.2910110303.

7

Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.

Br Med J. 1973 Dec 8;4(5892):571-3. doi: 10.1136/bmj.4.5892.571.

8

Three closely linked genetic systems relevant to transplantation.

Proc Natl Acad Sci U S A. 1971 Dec;68(12):3031-5. doi: 10.1073/pnas.68.12.3031.

9

Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

Br J Cancer. 1969 Dec;23(4):814-24. doi: 10.1038/bjc.1969.101.

10

Generation of cytotoxic T lymphocytes in vitro. II. Effect of repeated exposure to alloantigens on the cytotoxic activity of long-term mixed leukocyte cultures.

J Exp Med. 1974 Sep 1;140(3):718-30. doi: 10.1084/jem.140.3.718.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

急性髓系白血病患者免疫治疗导致的细胞介导的细胞毒性。

Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.

作者信息

Taylor G M, Harris R, Freeman C B

出版信息

Br J Cancer. 1976 Feb;33(2):137-43. doi: 10.1038/bjc.1976.18.

DOI:10.1038/bjc.1976.18

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2024940/

Abstract

Leucocytes from normal individuals and from patients with acute myeloid leukaemia (AML) in remission receiving active immunotherapy with allogeneic AML blasts (AML-I) were cultured for 6 days with AML-I blasts, Burkitt's lymphoma cells (BL) or lymphoblastoid cells (LCL). The leucocytes were then tested for cell-mediated cytotoxicity (CMC) against 51Cr-labelled AML-I, BL or LCL target cells. There was no substantial difference in the CMC of leucocytes from patients and normals cultured without stimulation, and tested against AML-I, BL or LCL targets. Patient's leucocytes stimulated in vitro with AML-I had a greater frequency of positive CMC responses against AML-I, BL and LCL than normal individuals. The results suggest that co-cultivation of leucocytes with AML-I blasts reactivates memory cytotoxic leucocytes in AML patients receiving immunotherapy and that this test may be useful in measuring the effectiveness of immunotherapy.

摘要

将来自正常个体以及处于缓解期且接受同种异体急性髓细胞白血病母细胞主动免疫治疗（AML-I）的急性髓细胞白血病（AML）患者的白细胞，与AML-I母细胞、伯基特淋巴瘤细胞（BL）或淋巴母细胞样细胞（LCL）共同培养6天。然后检测这些白细胞对51Cr标记的AML-I、BL或LCL靶细胞的细胞介导细胞毒性（CMC）。在未受刺激情况下培养并针对AML-I、BL或LCL靶细胞进行检测时，患者和正常人白细胞的CMC没有实质性差异。体外经AML-I刺激的患者白细胞对AML-I、BL和LCL的阳性CMC反应频率高于正常个体。结果表明，白细胞与AML-I母细胞共培养可使接受免疫治疗的AML患者体内的记忆性细胞毒性白细胞重新激活，并且该检测可能有助于评估免疫治疗的效果。